News Minimalist logo

Inventiva secures approval for prospectus to issue shares and warrants

globenewswire.com — October 14, 2024, 07:00 PM UTC

Summary: Inventiva has announced that the French financial authority, AMF, approved its prospectus for financing through the issuance of ordinary shares and pre-funded share warrants on October 14, 2024. This marks a new step in the company's funding efforts.

The prospectus includes a universal registration document and an amendment that incorporates the half-yearly financial report as of June 30, 2024. These documents are available on Inventiva's website and the AMF website.

Inventiva is focused on developing therapies for metabolic diseases, particularly MASH/NASH. Its lead candidate, lanifibranor, is in a Phase III trial, while the company has paused development on another candidate, odiparcil, to concentrate on lanifibranor.

Full article

Article metrics
Significance5.0
Scale & Impact5.3
Positivity6.2
Credibility8.5
What is this?

This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.

My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.

Read more about how I calculate significance, or see today's top ranked news on the main page:

See today's news rankings

Timeline:

  1. [4.8]
    Inventiva secures AMF approval for financing through share issuance (globenewswire.com)
    1d 4h
    Source
  2. [4.6]
    Inventiva secures AMF approval for financing through share issuance and warrants (benzinga.com)
    1d 4h
    Source
  3. [4.2]
    Inventiva stock rises after securing €94 million financing for fatty liver drug trial (benzinga.com)
    1d 7h
    Source
  4. [4.8]
    Inventiva files 2024 half-year report highlighting financial uncertainties (globenewswire.com)
    1d 16h
    Source
  5. [4.7]
    Inventiva secures €94 million to advance Phase 3 trial for MASH treatment (benzinga.com)
    1d 16h
    Source
  6. [4.7]
    Inventiva secures €348 million financing to advance Phase 3 MASH study (globenewswire.com)
    1d 16h
    Source
  7. [4.5]
    Inventiva files 2024 Half-Year Report with financial authority in France (benzinga.com)
    1d 16h
    Source